Der Spiegel

Sonntag, 19. Januar 2020


GlobeNewswire: Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan

05.12.2019, 07:00 Uhr

Idorsia and Mochida enter into a license agreement for the supply,
co-development and co-marketing of daridorexant in Japan

Allschwil, Switzerland - December 5, 2019

Idorsia Ltd (SIX: IDIA) and Mochida Pharmaceutical Co., Ltd. today announced
that they have entered into an exclusive license agreement for the supply,
co-development and co-marketing of daridorexant, Idorsia's dual orexin receptor
antagonist (DORA), for insomnia and related disorders in Japan.

Idorsia will receive an initial payment of 1 billion Japanese yen
(approximately 9 million Swiss francs) and will be entitled to three additional
development and regulatory milestones. Idorsia will also be entitled to sales
milestones and tiered royalty payments based on net sales achieved by Mochida.
Costs associated with the co-development of daridorexant will be shared.

With regards to the future development program, Idorsia will be responsible
for the design and conduct of additional preclinical and clinical studies, and
for health authority registration, with oversight from a Joint Development
Committee. Should Idorsia wish to out-license daridorexant for use in any field
other than insomnia and related disorders to a third party in Japan, Mochida
will be offered the right of first refusal.

Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, commented:
"Establishing Idorsia Pharmaceuticals Japan in 2018 under the leadership of Dr
Satoshi Tanaka has allowed us to forge a partnership with Mochida. I'm
confident that daridorexant is in very good hands. We now are eagerly waiting
for the data from the Phase 3 program to come mid-2020 and are looking forward
to be able to provide a new treatment option to the many patients suffering
from Insomnia."

Simon Jose, Chief Commercial Officer of Idorsia commented:
"Mochida is a very attractive partner for our DORA in Japan. They have an
established commercial presence and strong relationships with CNS and internal
medicine practitioners, key prescribers who take care of a large segment of
insomnia patients. Mochida also has a great track record of co-promotions with
international companies, most recently and notably for a very successful CNS
therapy. Based on their due diligence and knowledge of the market, Mochida's
commitment to the partnership before the Phase 3 results demonstrates that
Mochida shares our belief that daridorexant has great potential in a country
where DORAs are expected to play a significant role in the market."

Naoyuki Mochida, President of Mochida commented:
"We are excited to have entered into the agreement with Idorsia for the
supply, co-development and co-marketing of daridorexant. Since general internal
medicine and psychiatry, where insomnia patients are concentrated, are our
priority areas, we believe that our experience will be of great use. We will
endeavor to provide the drug to Japanese patients suffering from insomnia."

At present daridorexant is in a global (excluding Japan) Phase 3 confirmatory
program and a Phase 2, dose confirmation study in Japanese patients. Both are
expected to have data reading out as of mid-2020.


Notes to the editor

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into one of Europe's leading biopharmaceutical companies,
with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is
specialized in the discovery and development of small molecules, to transform
the horizon of therapeutic options. Idorsia has a broad portfolio of innovative
drugs in the pipeline, an experienced team, a fully-functional research center,
and a strong balance sheet - the ideal constellation to bringing R&D efforts to
business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.

About Mochida
Mochida Pharmaceutical Co., Ltd. has been committed to research and
development of innovative pharmaceutical products since its establishment
thereby providing distinctive medicines to the medical field. Currently, the
core pharmaceutical business focuses resources on the targeted areas of
cardiovascular medicine, obstetrics and gynecology, dermatology, psychiatry and
gastroenterology, while also providing medicine for intractable disease as well
as generics including biosimilars, to meet medical needs. For more information
on Mochida Pharmaceutical Co., Ltd., please see

For further information, please contact
For Idorsia:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects", "may",
"are expected to", "will", "will continue", "should", "would be", "seeks",
"pending" or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.

Anhang Medienmitteilung PDF

Weitere Nachrichten

15.01. BUSINESS WIRE: Scheich Mohammed bin Zayed ehrt die 10 Gewinner des Zayed-Nachhaltigkeitspreises 2020
15.01. BUSINESS WIRE: Mit der Einführung der Airtame Cloud signalisiert Airtame neuen Fokus auf kombiniertes Angebot aus Hardware und Software
15.01. BUSINESS WIRE: Vincent Hayward, Mitbegründer von Actronika, wird in die französische Akademie der Wissenschaften gewählt
15.01. BUSINESS WIRE: Bei HubHead Corp. ist man stolz darauf, das erste nordamerikanische Mitgliedsunternehmen der Open Industry 4.0 Alliance zu sein
15.01. BUSINESS WIRE: Emendo Biotherapeutics wirbt 61 Mio. USD zur Förderung von genomeditierenden Therapeutika der nächsten Generation ein
15.01. BUSINESS WIRE: KAL und Česká spořitelna schaffen mit Kalignite Hypervisor ATM in der Produktion eine Weltneuheit
15.01. BUSINESS WIRE: Temenos erreicht wichtigen Meilenstein mit der Einführung der Mikroservices-Architektur Temenos Transact, die großen Banken eine skalierende strategische Transformation ihrer Kernsysteme auf sichere und progressive Weise ermöglicht
15.01. BUSINESS WIRE: Sofinnova Partners gibt die Beförderung von Michael Krel zum Partner des Industrial Biotechnology Teams bekannt
15.01. BUSINESS WIRE: Fairy bringt zwei natürliche Düfte und eine parfümfreie Variante auf den Markt
15.01. BUSINESS WIRE: BOC Group und TIM Solutions verkünden strategische Partnerschaft zur Vereinfachung der Digitalisierung von Geschäftsprozessen